Pre-Exposure Prophylaxis, commonly referred to as PrEP medication, represents a biomedical prevention strategy designed to reduce the risk of HIV acquisition. This preventive approach involves the use of antiretroviral medications by individuals who do not have HIV but may face increased exposure risk. Over the past decade, PrEP has significantly influenced HIV prevention efforts across multiple regions, contributing to measurable declines in new infections in populations with consistent use. This article presents an informational overview of PrEP medication, including its mechanism of action, approved drug formulations, clinical effectiveness, safety considerations, eligibility criteria, adherence importance, and broader public health implications.
Understanding HIV and Prevention Strategies
Human Immunodeficiency Virus (HIV) attacks the immune system, specifically targeting CD4 cells that play a central role in immune defense. Without treatment, HIV may progress to Acquired Immunodeficiency Syndrome (AIDS), characterized by severe immune damage and vulnerability to opportunistic infections.
Prevention strategies historically included condom use, behavioral interventions, harm reduction programs, routine testing, and antiretroviral therapy for individuals living with HIV to reduce transmission risk. The development of PrEP medication added a pharmacological layer of prevention, expanding the spectrum of available biomedical tools.
What Is PrEP Medication?
PrEP medication consists of antiretroviral drugs taken before potential HIV exposure to reduce infection risk. These medications work by maintaining protective drug levels in the bloodstream and target tissues. If exposure occurs, the medication interferes with viral replication, preventing the virus from establishing permanent infection.
PrEP differs from Post-Exposure Prophylaxis (PEP), which is taken after a potential exposure event. PrEP functions as an ongoing preventive measure rather than an emergency intervention.
FDA-Approved PrEP Medications
Several medications have received regulatory approval for PrEP use in the United States by the U.S. Food and Drug Administration.
One widely recognized oral formulation is Truvada, a combination of emtricitabine and tenofovir disoproxil fumarate. This medication demonstrated strong preventive efficacy in multiple clinical trials across diverse populations.
Another oral medication is Descovy, which contains emtricitabine and tenofovir alafenamide. It is approved for certain populations based on clinical study data.
A long-acting injectable medication, Apretude, contains cabotegravir and is administered at scheduled intervals. This formulation offers an alternative to daily oral tablets and has demonstrated high efficacy in prevention studies.
Medication selection in clinical practice depends on individual health factors, risk profiles, and medical history.
Mechanism of Action
PrEP medications belong to the class of antiretroviral drugs known as nucleoside reverse transcriptase inhibitors or integrase strand transfer inhibitors, depending on the formulation. These medications block critical steps in the HIV replication process.
When HIV enters the body, it attempts to convert its RNA into DNA using an enzyme called reverse transcriptase. Some PrEP drugs inhibit this process, preventing viral DNA formation. Other formulations block integration of viral DNA into host cells. By interrupting replication at early stages, PrEP prevents systemic infection from becoming established.
Protective drug levels must be maintained for maximum effectiveness. For oral PrEP, consistent daily dosing supports steady-state drug concentrations in blood and mucosal tissues.
Clinical Effectiveness
Extensive research has evaluated PrEP effectiveness across populations, including men who have sex with men, heterosexual individuals at risk, transgender women, and people who inject drugs. When taken consistently, oral PrEP reduces the risk of sexually acquired HIV by approximately 99 percent. Protection against HIV transmission through injection drug use is also significantly reduced with adherence.
Long-acting injectable PrEP has demonstrated comparable or superior effectiveness in clinical trials when administered according to prescribed schedules.
Adherence plays a central role in prevention success. Missed doses or delayed injections may reduce protective drug levels and compromise effectiveness.
Eligibility and Risk Assessment
Healthcare providers assess multiple factors when determining PrEP eligibility. These factors may include sexual exposure patterns, known HIV-positive partners, inconsistent condom use, history of sexually transmitted infections, or injection drug use involving shared equipment.
Baseline HIV testing is required before starting PrEP to confirm negative status. Ongoing monitoring is also necessary to ensure continued HIV-negative status during use.
Kidney function testing may be required for certain oral formulations, as some medications can influence renal parameters. Liver function and other laboratory assessments may also be incorporated into routine follow-up.